The Cancer Genetics (CGIX) Receives Daily News Sentiment Score of 0.40

The Cancer Genetics (CGIX) Receives Daily News Sentiment Score of 0.40

These are some of the headlines that may have effected AlphaOne’s scoring:

Media coverage about Cancer Genetics (NASDAQ:CGIX) has trended positive on Monday, according to Alpha One Sentiment Analysis. The research firm, a service of Accern, scores the sentiment of news coverage by analyzing more than twenty million blog and news sources. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cancer Genetics earned a news sentiment score of 0.40 on Alpha One’s scale. Alpha One also gave news headlines about the medical research company an impact score of 96 out of 100, meaning that recent news coverage is extremely likely to have an impact on the company’s share price in the near future.

Shares of Cancer Genetics (NASDAQ:CGIX) opened at 3.90 on Monday. Cancer Genetics has a 1-year low of $1.10 and a 1-year high of $5.30. The stock’s market capitalization is $77.07 million. The company has a 50-day moving average of $3.99 and a 200-day moving average of $2.65. Cancer Genetics (NASDAQ:CGIX) last posted its earnings results on Thursday, May 11th. The medical research company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.07. Cancer Genetics had a negative return on equity of 63.26% and a negative net margin of 74.07%. The business had revenue of $7 million during the quarter, compared to analyst estimates of $7.62 million. During the same quarter last year, the firm earned ($0.39) earnings per share. The company’s revenue for the quarter was up 14.8% compared to the same quarter last year. On average, equities research analysts expect that Cancer Genetics will post ($0.86) EPS for the current fiscal year.

About Cancer Genetics Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:CGIX”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Cancer Genetics Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cancer Genetics Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment